Antibody-induced  ||| S:0 E:17 ||| JJ
failure  ||| S:17 E:25 ||| NN
of  ||| S:25 E:28 ||| IN
botulinum  ||| S:28 E:38 ||| JJ
toxin  ||| S:38 E:44 ||| NN
a  ||| S:44 E:46 ||| DT
therapy  ||| S:46 E:54 ||| NN
in  ||| S:54 E:57 ||| IN
cosmetic  ||| S:57 E:66 ||| JJ
indications  ||| S:66 E:78 ||| NNS
Botulinum  ||| S:78 E:88 ||| JJ
toxin  ||| S:88 E:94 ||| NN
( ||| S:94 E:95 ||| -LRB-
BT ||| S:95 E:97 ||| NNP
)  ||| S:97 E:99 ||| -RRB-
is  ||| S:99 E:102 ||| VBZ
a  ||| S:102 E:104 ||| DT
safe  ||| S:104 E:109 ||| JJ
and  ||| S:109 E:113 ||| CC
effective  ||| S:113 E:123 ||| JJ
treatment  ||| S:123 E:133 ||| NN
for  ||| S:133 E:137 ||| IN
cosmetic  ||| S:137 E:146 ||| JJ
indications ||| S:146 E:157 ||| NNS
.  ||| S:157 E:159 ||| .
Formation  ||| S:159 E:169 ||| NN
of  ||| S:169 E:172 ||| IN
BT  ||| S:172 E:175 ||| NNP
antibodies  ||| S:175 E:186 ||| NNS
can  ||| S:186 E:190 ||| MD
occur  ||| S:190 E:196 ||| VB
but  ||| S:196 E:200 ||| CC
has  ||| S:200 E:204 ||| VBZ
previously  ||| S:204 E:215 ||| RB
been  ||| S:215 E:220 ||| VBN
reported  ||| S:220 E:229 ||| VBN
in  ||| S:229 E:232 ||| IN
cosmetic  ||| S:232 E:241 ||| JJ
indications  ||| S:241 E:253 ||| NNS
in  ||| S:253 E:256 ||| IN
two  ||| S:256 E:260 ||| CD
cases  ||| S:260 E:266 ||| NNS
only ||| S:266 E:270 ||| RB
.  ||| S:270 E:272 ||| .
To  ||| S:272 E:275 ||| TO
report  ||| S:275 E:282 ||| VB
another  ||| S:282 E:290 ||| DT
four  ||| S:290 E:295 ||| CD
patients  ||| S:295 E:304 ||| NNS
with  ||| S:304 E:309 ||| IN
this  ||| S:309 E:314 ||| DT
phenomenon ||| S:314 E:324 ||| NN
.  ||| S:324 E:326 ||| .
Two  ||| S:326 E:330 ||| CD
patients  ||| S:330 E:339 ||| NNS
received  ||| S:339 E:348 ||| VBD
abobotulinumtoxinA ||| S:348 E:366 ||| JJ
;  ||| S:366 E:368 ||| :
one  ||| S:368 E:372 ||| CD
received  ||| S:372 E:381 ||| VBD
the  ||| S:381 E:385 ||| DT
current  ||| S:385 E:393 ||| JJ
formulation  ||| S:393 E:405 ||| NN
of  ||| S:405 E:408 ||| IN
onabotulinumtoxinA  ||| S:408 E:427 ||| JJ
and  ||| S:427 E:431 ||| CC
one  ||| S:431 E:435 ||| CD
both  ||| S:435 E:440 ||| DT
abobotulinumtoxinA  ||| S:440 E:459 ||| JJ
and  ||| S:459 E:463 ||| CC
onabotulinumtoxinA ||| S:463 E:481 ||| JJ
.  ||| S:481 E:483 ||| .
Complete  ||| S:483 E:492 ||| JJ
secondary  ||| S:492 E:502 ||| JJ
therapy  ||| S:502 E:510 ||| NN
failure  ||| S:510 E:518 ||| NN
( ||| S:518 E:519 ||| -LRB-
CSTF ||| S:519 E:523 ||| NNP
)  ||| S:523 E:525 ||| -RRB-
occurred  ||| S:525 E:534 ||| VBD
after  ||| S:534 E:540 ||| IN
3- ||| S:540 E:542 ||| NNP
,  ||| S:542 E:544 ||| ,
5- ||| S:544 E:546 ||| NNP
,  ||| S:546 E:548 ||| ,
10- ||| S:548 E:551 ||| NNP
,  ||| S:551 E:553 ||| ,
and  ||| S:553 E:557 ||| CC
13-injection  ||| S:557 E:570 ||| CD
series ||| S:570 E:576 ||| NN
;  ||| S:576 E:578 ||| :
cumulative  ||| S:578 E:589 ||| JJ
treatment  ||| S:589 E:599 ||| NN
times  ||| S:599 E:605 ||| NNS
of  ||| S:605 E:608 ||| IN
18 ||| S:608 E:610 ||| CD
,  ||| S:610 E:612 ||| ,
16 ||| S:612 E:614 ||| CD
,  ||| S:614 E:616 ||| ,
25 ||| S:616 E:618 ||| CD
,  ||| S:618 E:620 ||| ,
and  ||| S:620 E:624 ||| CC
65  ||| S:624 E:627 ||| CD
months ||| S:627 E:633 ||| NNS
;  ||| S:633 E:635 ||| :
and  ||| S:635 E:639 ||| CC
cumulative  ||| S:639 E:650 ||| JJ
doses  ||| S:650 E:656 ||| NNS
of  ||| S:656 E:659 ||| IN
240  ||| S:659 E:663 ||| CD
MU  ||| S:663 E:666 ||| NNP
onabotulinumtoxinA ||| S:666 E:684 ||| NNP
,  ||| S:684 E:686 ||| ,
245  ||| S:686 E:690 ||| CD
MU  ||| S:690 E:693 ||| NNP
abobotulinumtoxinA ||| S:693 E:711 ||| NNP
,  ||| S:711 E:713 ||| ,
1,180  ||| S:713 E:719 ||| NNP
MU  ||| S:719 E:722 ||| NNP
abobotulinumtoxinA ||| S:722 E:740 ||| NNP
,  ||| S:740 E:742 ||| ,
and  ||| S:742 E:746 ||| CC
120  ||| S:746 E:750 ||| CD
MU  ||| S:750 E:753 ||| NNP
onabotulinumtoxinA ||| S:753 E:771 ||| NNP
/ ||| S:771 E:772 ||| CD
270  ||| S:772 E:776 ||| CD
MU  ||| S:776 E:779 ||| NNP
abobotulinumtoxinA ||| S:779 E:797 ||| NNP
,  ||| S:797 E:799 ||| ,
respectively ||| S:799 E:811 ||| RB
.  ||| S:811 E:813 ||| .
Average  ||| S:813 E:821 ||| JJ
interinjection  ||| S:821 E:836 ||| JJ
intervals  ||| S:836 E:846 ||| NNS
were  ||| S:846 E:851 ||| VBD
87 ||| S:851 E:853 ||| CD
,  ||| S:853 E:855 ||| ,
273 ||| S:855 E:858 ||| CD
,  ||| S:858 E:860 ||| ,
150 ||| S:860 E:863 ||| CD
,  ||| S:863 E:865 ||| ,
and  ||| S:865 E:869 ||| CC
119  ||| S:869 E:873 ||| CD
days ||| S:873 E:877 ||| NNS
,  ||| S:877 E:879 ||| ,
and  ||| S:879 E:883 ||| CC
average  ||| S:883 E:891 ||| JJ
single  ||| S:891 E:898 ||| JJ
doses  ||| S:898 E:904 ||| NNS
were  ||| S:904 E:909 ||| VBD
80  ||| S:909 E:912 ||| CD
MU  ||| S:912 E:915 ||| NNP
onabotulinumtoxinA ||| S:915 E:933 ||| NNP
,  ||| S:933 E:935 ||| ,
68  ||| S:935 E:938 ||| CD
MU  ||| S:938 E:941 ||| NNP
abobotulinumtoxinA ||| S:941 E:959 ||| NNP
,  ||| S:959 E:961 ||| ,
82  ||| S:961 E:964 ||| CD
MU  ||| S:964 E:967 ||| NNP
abobotulinumtoxinA ||| S:967 E:985 ||| NNP
,  ||| S:985 E:987 ||| ,
and  ||| S:987 E:991 ||| CC
30  ||| S:991 E:994 ||| CD
MU  ||| S:994 E:997 ||| NNP
abobotulinumtoxinA ||| S:997 E:1015 ||| NNP
/ ||| S:1015 E:1016 ||| CD
30  ||| S:1016 E:1019 ||| CD
MU  ||| S:1019 E:1022 ||| NNP
onabotulinumtoxinA ||| S:1022 E:1040 ||| NNP
.  ||| S:1040 E:1042 ||| .
Risk  ||| S:1042 E:1047 ||| NN
factors  ||| S:1047 E:1055 ||| NNS
for  ||| S:1055 E:1059 ||| IN
CSTF  ||| S:1059 E:1064 ||| NNP
included  ||| S:1064 E:1073 ||| VBD
booster  ||| S:1073 E:1081 ||| JJ
injections  ||| S:1081 E:1092 ||| NNS
( ||| S:1092 E:1093 ||| -LRB-
2  ||| S:1093 E:1095 ||| CD
patients ||| S:1095 E:1103 ||| NNS
)  ||| S:1103 E:1105 ||| -RRB-
and  ||| S:1105 E:1109 ||| CC
increased  ||| S:1109 E:1119 ||| VBD
immune  ||| S:1119 E:1126 ||| JJ
system  ||| S:1126 E:1133 ||| NN
reagibility  ||| S:1133 E:1145 ||| NNS
( ||| S:1145 E:1146 ||| -LRB-
1  ||| S:1146 E:1148 ||| CD
patient ||| S:1148 E:1155 ||| NN
) ||| S:1155 E:1156 ||| -RRB-
.  ||| S:1156 E:1158 ||| .
BT  ||| S:1158 E:1161 ||| NNP
antibody  ||| S:1161 E:1170 ||| NN
titers  ||| S:1170 E:1177 ||| NNS
were  ||| S:1177 E:1182 ||| VBD
2.7 ||| S:1182 E:1185 ||| CD
,  ||| S:1185 E:1187 ||| ,
7.0 ||| S:1187 E:1190 ||| CD
,  ||| S:1190 E:1192 ||| ,
and  ||| S:1192 E:1196 ||| CC
more  ||| S:1196 E:1201 ||| JJR
than  ||| S:1201 E:1206 ||| IN
10.0  ||| S:1206 E:1211 ||| NNP
mU ||| S:1211 E:1213 ||| NNP
/ ||| S:1213 E:1214 ||| NNP
mL  ||| S:1214 E:1217 ||| NNP
on  ||| S:1217 E:1220 ||| IN
the  ||| S:1220 E:1224 ||| DT
mouse  ||| S:1224 E:1230 ||| NN
diaphragm  ||| S:1230 E:1240 ||| NN
assay ||| S:1240 E:1245 ||| NN
.  ||| S:1245 E:1247 ||| .
CSTF  ||| S:1247 E:1252 ||| NNP
can  ||| S:1252 E:1256 ||| MD
occur  ||| S:1256 E:1262 ||| VB
after  ||| S:1262 E:1268 ||| IN
cosmetic  ||| S:1268 E:1277 ||| JJ
BT  ||| S:1277 E:1280 ||| NNP
injections  ||| S:1280 E:1291 ||| NNS
in  ||| S:1291 E:1294 ||| IN
patients  ||| S:1294 E:1303 ||| NNS
with  ||| S:1303 E:1308 ||| IN
high  ||| S:1308 E:1313 ||| JJ
immune  ||| S:1313 E:1320 ||| JJ
system  ||| S:1320 E:1327 ||| NN
reagibility  ||| S:1327 E:1339 ||| NNS
and  ||| S:1339 E:1343 ||| CC
in  ||| S:1343 E:1346 ||| IN
patients  ||| S:1346 E:1355 ||| NNS
receiving  ||| S:1355 E:1365 ||| VBG
booster  ||| S:1365 E:1373 ||| JJ
injections ||| S:1373 E:1383 ||| NNS
,  ||| S:1383 E:1385 ||| ,
but  ||| S:1385 E:1389 ||| CC
also  ||| S:1389 E:1394 ||| RB
in  ||| S:1394 E:1397 ||| IN
unremarkable  ||| S:1397 E:1410 ||| JJ
patients  ||| S:1410 E:1419 ||| NNS
with  ||| S:1419 E:1424 ||| IN
typical  ||| S:1424 E:1432 ||| JJ
treatment  ||| S:1432 E:1442 ||| NN
parameters ||| S:1442 E:1452 ||| NNS
.  ||| S:1452 E:1454 ||| .
Its  ||| S:1454 E:1458 ||| PRP$
incidence  ||| S:1458 E:1468 ||| NN
is  ||| S:1468 E:1471 ||| VBZ
unknown ||| S:1471 E:1478 ||| JJ
.  ||| S:1478 E:1480 ||| .
Recommended  ||| S:1480 E:1492 ||| JJ
treatment  ||| S:1492 E:1502 ||| NN
parameters  ||| S:1502 E:1513 ||| NNS
may  ||| S:1513 E:1517 ||| MD
reduce  ||| S:1517 E:1524 ||| VB
the  ||| S:1524 E:1528 ||| DT
risk  ||| S:1528 E:1533 ||| NN
of  ||| S:1533 E:1536 ||| IN
CSTF ||| S:1536 E:1540 ||| NNP
,  ||| S:1540 E:1542 ||| ,
but  ||| S:1542 E:1546 ||| CC
may  ||| S:1546 E:1550 ||| MD
not  ||| S:1550 E:1554 ||| RB
eliminate  ||| S:1554 E:1564 ||| VB
it ||| S:1564 E:1566 ||| PRP
.  ||| S:1566 E:1568 ||| .
